[HTML][HTML] Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act
A Tefferi - Bone Marrow Transplantation, 2010 - nature.com
Primary myelofibrosis (PMF) is a chronic myeloid malignancy characterized by stem cell-
derived clonal myeloproliferation, anemia, marked hepatosplenomegaly and other …
derived clonal myeloproliferation, anemia, marked hepatosplenomegaly and other …
Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act
A Tefferi - Bone Marrow Transplantation, 2010 - go.gale.com
Primary myelofibrosis (PMF) is a chronic myeloid malignancy characterized by stem cell-
derived clonal myeloproliferation, anemia, marked hepatosplenomegaly and other …
derived clonal myeloproliferation, anemia, marked hepatosplenomegaly and other …
[引用][C] Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act
A Tefferi - Bone marrow transplantation, 2010 - pubmed.ncbi.nlm.nih.gov
[引用][C] Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act
A TEFFERI - Bone Marrow Transplant., 2010 - cir.nii.ac.jp
Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis : the risk-benefit
balancing act | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
balancing act | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
[引用][C] Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act.
A Tefferi - Bone Marrow Transplantation, 2010 - europepmc.org
Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit
balancing act. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe …
balancing act. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe …
Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act.
A Tefferi - Bone Marrow Transplantation, 2010 - search.ebscohost.com
The article discusses the treatment of primary myelofibrosis (PMF), a chronic myeloid
malignancy. It states that conventional drugs such as androgen preparation and stimulating …
malignancy. It states that conventional drugs such as androgen preparation and stimulating …
[引用][C] Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: The risk-benefit balancing act
A Tefferi - Bone Marrow Transplantation, 2010 - mayoclinic.elsevierpure.com
Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: The risk-benefit
balancing act — Mayo Clinic Skip to main navigation Skip to search Skip to main content Mayo …
balancing act — Mayo Clinic Skip to main navigation Skip to search Skip to main content Mayo …